ALX Oncology Q2 net loss $25.9M; cash runway into Q1 2027; CD47 biomarker data highlights evorpacept potential

ALX ONCOLOGY HOLDINGS INC

2025-Q2 EPS reported -$1.05

GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.
Cash, equivalents & investments $83.5M; runway extended into Q1 2027 after pausing ASPEN-CRC trial.
ASPEN-06 analysis: CD47-high HER2+ gastric cancer patients had 65% ORR with evorpacept + TRP vs 26% TRP alone; full data Q4 2025.
ASPEN-Breast amended to single-arm biomarker-driven study; interim data expected Q3 2026.
ALX2004 Phase 1 first patient dosing in August 2025; initial safety data 1H2026. Allison Dillon appointed COO; Daniel Curran appointed to Board.

item 2.02item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.